+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

COVID-19 Testing Market Update, 2022

  • PDF Icon


  • 67 Pages
  • April 2022
  • Region: Global
  • Kalorama Information
  • ID: 5578594
This report, COVID-19 Testing Market Update, 2022, provides market sizing and estimates for COVID-19 tests with some discussion of market impacts of COVID-19.  The scourge of COVID-19 continued to occupy laboratories and the in vitro diagnostic (IVD) companies that serve them throughout 2021 and into 2022.  Testing already present in large labs and clinics entered the home last year, which added to market revenues.

At the time of publication, there is a slight decrease in cases which might suggest a decrease in COVID-19 testing revenues, but we’ve been through this before. Predicting COVID-19 is not easy.  For the past two years, the disease has confounded prediction.  There are at least two schools of thought about 2022.  One is that COVID, as a result of the highly contagious Omicron and Delta variants, exposed enough of the population to have antibodies, and this along with strong vaccination rates and boostering, makes COVID-19 a still present but waning disease. Even in this optimistic scenario, testing will be at high volume and remains necessary throughout 2022, but there would be a decline in revenues.

A more pessimistic disease scenario would be that there are other variants that prove to be contagious, and vaccines do not provide enough long term protection and the population isn’t boostering at high levels. This would represent another wave like that seen during Q4 2021 and might suggest that such waves will be with us for some time. The second scenario obviously would create COVID-19 testing revenues and volumes higher than 2021.

COVID-19 Testing Market Update, 2022 covers these topics, trends, and predictions, in addition to providing other essential market analysis.

Table of Contents

Chapter 1: Executive Summary
  • COVID-19 Testing Market Demand and Growth
  • Figure 1-1: COVID Market 2020 vs. 2021, ($billions)
  • Figure 1-2: COVID Testing by Quarter 2021, ($millions)
  • Figure 1-3: COVID-19 Test Market by Type, Q1-Q4 2021 Trend (Serology, Antigen, Molecular, Rapid) ($millions)
  • Growth Outlook
  • Figure 1-4: Growth Outlook for COVID-19 Testing, 2021 -2023 (percent)
  • Country Distribution
  • Figure 1-5: COVID-19 Revenue by Country, 2021
  • Test Innovations and Approvals
  • Table 1-1: Recent COVID-19 Test Approvals and Innovations

Chapter 2: Trends and Developments
  • Antigen and Molecular Product Developments
  • Antigen
  • Molecular
  • Other Developments
  • COVID-19 Testing Expands Multiplex Testing
  • COVID-19 Drives Molecular Point of Care Growth
  • AI Mines CT,  Lab Results to Predict COVID-19 Severity
  • Long COVID Can Be Predicted Early On
  • Spectroscopy Employed in COVID-19

Chapter 3: Market Analysis COVID Testing
  • Market Analysis: Molecular, Antigen, Antibody and Rapid Tests
  • Table 3-1: COVID-19 Product Sales by Type - Immunoassay, Molecular, Rapid [at home, professional POC], 2021 ($ millions)
  • COVID-19 Test Market Share
  • Figure 3-1: COVID-19 Testing Market Share, 2021
  • COVID-19 Test Market by Country
  • Table 3-2: COVID-19 Market by Country  (India, China, UK, Germany, Spain, Italy, France, Mexico
  • US, Canada, Japan, Africa / Middle East, Rest of World)

Chapter 4: Top IVD Market Participants
  • Abbott Laboratories
  • Table 4-1: Abbott Corporate Summary
  • Figure 4-1: Abbott Diagnostics Revenue by Segment (Core Laboratory, Molecular, Point-of-Care, Rapid Diagnostics, COVID-19, BinaxNOW/ID NOW) Full Year, 2020 and 2021
  • Figure 4-2: COVID-19 Distribution of Diagnostic Test Sales, Abbott Laboratories
  • Table 4-2: COVID-19 Test Sales, Abbott Laboratories
  • Becton Dickinson
  • Table 4-3: Becton Dickinson Corporate Summary
  • bioMérieux SA
  • Table 4-4: bioMérieux Corporate Summary
  • Figure 4-3: bioMérieux Clinical Applications Segment, Full Year Results, 2020,2021
  • Danaher Corporation
  • Table 4-5: Danaher Corporation Summary
  • Recent Results
  • Figure 4-4: Danaher Diagnostic Segment Performance, Full Year Results, 2020,2021
  • Hologic, Inc.
  • Table 4-6: Hologic Corporate Summary
  • Recent Results
  • Figure 4-5: Hologic Diagnostic Segment Performance, Full Year Results, FY 2020, FY 2021, $M
  • Qiagen
  • Table 4-7: Qiagen Corporate Summary
  • Recent Results
  • Figure 4-6: QIAGEN Revenue Mix Distribution by Business Segment (Molecular Diagnostics, Life Sciences), Q3 2021
  • Figure 4-7: QIAGEN Sales by Product Group (Sample Technologies, Diagnostic Solutions, PCR/Nucleic Acid Amplification, Genomics/NGS, Other), Q3 2021 ($ millions)
  • Quidel Corporation
  • Table 4-8: Quidel Corporate Summary
  • Recent Results
  • Figure 4-8: Quidel Corporation Revenue by Product Group, Full Year Results 2020, 2021, $M
  • Roche Diagnostics
  • Table 4-9: Roche Diagnostic Corporate Summary
  • Recent Results
  • Figure 4-9: Roche Diagnostics Revenue by Product Group, Full Year Results, 2020, 2021, CHF MN
  • Figure 4-10: Roche COVID-19 Testing by Segment (PCR, Antigen & Serology), Quarterly Reports, 2020 and 2021
  • Siemens Healthineers
  • Table 4-10: Siemens Healthineers Corporate Summary
  • Recent Results
  • Figure 4-11: Siemens Diagnostics Revenue, FY 2020 and FY 2021, € MN
  • Thermo Fisher Scientific
  • Table 4-11: Thermo Fisher Scientific Corporate Summary
  • Recent Results
  • Figure 4-12: Thermo Fisher Scientific COVID-19 Response Revenue, 2020 and 2021 by Quarter
  • COVID-19 Test Providers
  • Table 4-12: Test Companies with an EUA-Issued COVID-19 Test (Company, Location, Test Product, Date EUA)

Companies Mentioned

  • Abbott Laboratories
  • Becton Dickinson
  • bioMérieux
  • Danaher Corporation
  • Hologic
  • Qiagen
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens
  • Thermo Fisher Scientific